TG Therapeutics - TGTX Stock Forecast, Price & News

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of TG Therapeutics in a research report on Monday, May 9th. HC Wainwright dropped their target price on shares of TG Therapeutics from $68.00 to $19.00 and set a "buy" rating on the stock in a research report on Monday, April 18th. StockNews.com upgraded shares of TG Therapeutics to a "sell" rating in a research report on Friday, June 17th. Bank of America started coverage on shares of TG Therapeutics in a research report on Friday, May 20th. They issued an "underperform" rating on the stock. Finally, B. Riley dropped their target price on shares of TG Therapeutics from $23.00 to $17.00 and set a "buy" rating on the stock in a research report on Monday, June 13th. Three investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $21.25.

TG Therapeutics Price Performance

TGTX traded down $0.22 on Friday, reaching $6.23. 5,386,164 shares of the company's stock were exchanged, compared to its average volume of 2,447,878. TG Therapeutics has a twelve month low of $3.48 and a twelve month high of $35.94. The stock's fifty day moving average price is $5.14 and its 200-day moving average price is $7.66. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.43 and a current ratio of 4.43.

TG Therapeutics (NASDAQ:TGTX - Get Rating) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.04. TG Therapeutics had a negative net margin of 4,126.45% and a negative return on equity of 118.49%. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $1.54 million. On average, analysts anticipate that TG Therapeutics will post -2.1 EPS for the current year.